If you or your loved one has relapsed Chronic Lymphocytic Leukemia (#CLL), an important new clinical trial may be an option.
New cancer treatment guidelines say repeated genetic testing is important to making the right treatment decisions and improving outcomes in patients with CLL. As part of the study, participants will receive genetic testing at no cost. This trial is testing whether adding an investigational medication (ublituximab) to ibrutinib (Imbruvica®), an FDA-approved treatment, improves outcomes for high-risk CLL patients.
If you are interested, the full study details and eligibility criteria are listed here.